

3/25/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), AVEO Oncology, Inc. is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on 3/24/2021. The new product being launched is:

- Fotivada Oral Capsule .89mg/cap: 45629-0089-01
- Fotivada Oral Capsule 1.34mg/cap: 45629-0134-01

Sincerely,

John Whitridge

Consultant